Beacon Therapeutics

Millions of people lose their sight due to retinal diseases – with no effective treatments, many sufferers are legally blind by the age of 45.

Beacon Therapeutics is developing gene therapies that target the genetic causes of retinal degeneration, in diseases such as the widespread dry age-related macular degeneration (dAMD) and rarer X-linked retinitis pigmentosa (XLRP). By delivering therapeutic genes directly to the retina, their approach aims to restore and preserve vision in patients with both rare and common eye conditions.

Spun out from the research of Oxford Professor of Ophthalmology Robert MacLaren, with support from Syncona and OSE, the company is bringing new hope where conventional medicine can’t.